- Report
- January 2025
- 308 Pages
Global
From €7558EUR$7,950USD£6,349GBP
- Report
- May 2019
- 17 Pages
Global
From €594EUR$625USD£499GBP
€1188EUR$1,250USD£998GBP
- Drug Pipelines
- February 2024
- 60 Pages
Global
From €1426EUR$1,500USD£1,198GBP
- Clinical Trials
- January 2024
- 60 Pages
Global
From €1188EUR$1,250USD£998GBP
- Report
- April 2023
- 114 Pages
Global
From €4516EUR$4,750USD£3,794GBP
- Report
- May 2022
- 81 Pages
Global
From €3500EUR$3,944USD£3,043GBP
- Report
- March 2025
- 81 Pages
Global
From €3500EUR$3,944USD£3,043GBP
- Report
- May 2022
- 55 Pages
Global
From €2377EUR$2,500USD£1,997GBP
- Report
- May 2022
- 46 Pages
Global
From €2377EUR$2,500USD£1,997GBP
- Report
- May 2022
- 43 Pages
Global
From €2377EUR$2,500USD£1,997GBP
- Report
- May 2022
- 58 Pages
Global
From €2377EUR$2,500USD£1,997GBP
- Report
- May 2022
- 134 Pages
Global
From €3327EUR$3,500USD£2,795GBP
Interleukin 2 (IL-2) is a cytokine used in immunosuppressive drug therapy. It is used to treat autoimmune diseases, such as rheumatoid arthritis, psoriasis, and Crohn's disease. IL-2 works by suppressing the immune system, which helps to reduce inflammation and pain. It is also used to treat certain types of cancer, such as renal cell carcinoma and melanoma.
IL-2 is available in both injectable and oral forms. The injectable form is administered intravenously, while the oral form is taken as a pill. The dosage and frequency of administration depend on the patient's condition and the severity of the disease.
The IL-2 market is highly competitive, with many companies offering different formulations of the drug. Some of the major players in the market include Novartis, Pfizer, Merck, and Bristol-Myers Squibb. Other companies include Amgen, Genentech, and Eli Lilly. Show Less Read more